Bitcoin 
Ethereum 
Tether 
XRP 
BNB 
USDC 
Solana 
TRON 
Lido Staked Ether 
Figure Heloc 
US President Donald Trump signed an executive order that could slap up to 100% on certain imported medicines from companies that don’t reach deals with his administration in the coming months, Bloomberg reported on Thursday.
💡 DMK Insight
Trump’s new executive order on imported medicines could shake up healthcare stocks and related markets. If companies face tariffs up to 100%, it could lead to higher drug prices and impact profit margins. Traders should watch pharmaceutical stocks closely, especially those heavily reliant on imports. This move could also ripple into the broader healthcare sector, affecting ETFs and indices tied to healthcare. Keep an eye on key stocks like Pfizer and Johnson & Johnson, which may react sharply to these developments. The real story here is how these tariffs could change the competitive landscape, potentially favoring domestic producers. Watch for any immediate market reactions, especially if companies announce their strategies to cope with these tariffs in the coming weeks. The next earnings reports could provide critical insights into how firms are adapting to this new reality.
📮 Takeaway
Monitor pharmaceutical stocks like Pfizer and J&J for volatility as Trump’s tariff plan unfolds; key earnings reports in the next few weeks will be crucial.
